XFOR — X4 Pharmaceuticals, Inc
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1501697 ·
Last close
$3.01
Market Cap
$298.43M
52W High
$4.83
52W Low
$2.80
ADV30
950,940
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 8,806,000 | 7,189,000 | -16,391,000 | -16,157,000 | 253,063,000 | 195,095,000 | 97,609,000 |
| Mar 2026 | 2,708,000 | 2,110,000 | -20,306,000 | -20,241,000 | 270,281,000 | 216,908,000 | 101,831,000 |
| Dec 2025 | 2,568,000 | 2,204,000 | -23,699,000 | -23,925,000 | 290,461,000 | 217,049,000 | 104,171,000 |
| Sep 2025 | 1,765,000 | 1,414,000 | -27,509,000 | -29,815,000 | 163,555,000 | 69,632,000 | 101,936,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-83,736,000
Investing CF
$6,432,000
Financing CF
$233,074,000
CapEx
$-3,041,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.45
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-630,952,000
Inventory
$5,502,000
Receivables
$2,047,000
ST Investments
$12,874,000
EBIT TTM
$-81,425,000
Pretax Income TTM
$-90,166,000
Interest Exp TTM
$8,741,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$15,847,000
EBITDA
$-79,004,000
Free Cash Flow
$-53,310,876
Enterprise Value
$216,268,608
Total Cash
$207,968,992
Total Debt
$77,224,000
Shares Out
99,146,743
Trailing EPS
$1.43
Book Value
$1.62
ROE
-113.1%
ROA
-28.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 35,113,000 | -86,883,000 | -79,199,000 | 290,461,000 | 104,171,000 | 186,290,000 | -85,618,000 |
| Dec 2024 | 2,557,000 | -141,401,000 | -37,450,000 | 146,447,000 | 124,298,000 | 22,149,000 | -130,901,000 |
| Dec 2023 | 0 | -107,522,000 | -101,167,000 | 147,258,000 | 96,159,000 | 51,099,000 | -96,512,000 |
| Dec 2022 | 0 | -88,078,000 | -93,867,000 | 155,586,000 | 81,535,000 | 74,051,000 | -77,102,000 |
TTM Snapshot
Revenues TTM
$29,367,000
NetIncome TTM
$-36,414,000
OpCashFlow TTM
$0
Assets (Latest)
$290,461,000
Forward EPS
$-0.77
Max Pain — expiry 2026-12-18
max pain strike: $2.50 · spot: $3.03 · call oi: 5,212 · put oi: 0
Expected Move to 2026-12-18:
±$2.15
(71.07%) —
implied range
$0.88 –
$5.18
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SABS | SAB Biotherapeutics, Inc. | $299.35M | $3.29 | — |
| IPSC | Century Therapeutics, Inc. | $302.40M | $1.67 | — |
| IKT | Inhibikase Therapeutics, Inc. | $287.44M | $2.06 | — |
| FATE | FATE THERAPEUTICS INC | $281.58M | $2.35 | — |
| IVVD | Invivyd, Inc. | $275.30M | $0.93 | — |
News headlines (Yahoo Finance, 1h cache)
Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround
2026-09-24 12:35 · Yahoo
X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-09-11 13:35 · Yahoo
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
2026-09-08 11:00 · Yahoo
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-01 20:30 · Yahoo
X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates
2026-08-06 23:10 · Yahoo
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-06 20:15 · Yahoo
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-07 20:30 · Yahoo
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
2026-07-01 11:00 · Yahoo
X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-27 11:00 · Yahoo
How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress
2026-05-21 04:33 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.